Episodebeskrivelse
Moderna jumped roughly 130–137% in a single day this week on a major mRNA cancer breakthrough: a personalized cancer shot, built using AI to sequence a patient's own tumor, completed Phase 3 trials with strong results. The hosts trace it back to Keytruda, the immunotherapy drug that's driven much of Merck's revenue for about 14 years, which works by helping the immune system detect cancer that would otherwise hide from it. Moderna's shot goes a step further, tailoring treatment to each patien...

